Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab...

Full description

Saved in:

Bibliographic Details
Published in:	BMC neurology Vol. 20; no. 1; pp. 25 - 18
Main Authors:	Bangs, Mark E., Kudrow, David, Wang, Shufang, Oakes, Tina M., Terwindt, Gisela M., Magis, Delphine, Yunes-Medina, Laura, Stauffer, Virginia L.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 17.01.2020 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Blood Blood pressure Calcitonin Calcitonin gene-related peptide Cardiovascular disease CGRP Clinical trials Comorbidity Constipation Demographics Diabetes Disease prevention Double-Blind Method Drug dosages Drug therapy EKG Electrocardiography Family medical history Female Galcanezumab Headache Headaches Humans Hyperglycemia Hypertension Immunoglobulins Injection Laboratories Male Medicine Medicine & Public Health Middle Aged Migraine Migraine Disorders - drug therapy Monoclonal antibodies Neurochemistry Neurology Neurosurgery Pain Patients Population Pruritus Randomized Controlled Trials as Topic Research Article Safety Studies Suicides & suicide attempts Tolerability Treatment Outcome Vertigo Vital signs North America Galcanezumab Tolerability Safety CGRP Migraine
ISSN:	1471-2377, 1471-2377
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!